A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

NCT05587322 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-erosive Reflux Disease

Interventions

DRUG: BLI5100
DRUG: Placebo

Sponsor

Braintree Laboratories